Zymeworks Inc.
ZYME
Jodie situation report
Zymeworks Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 12 of 13 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.
- At least 9 of 13 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ATAI begins moving with the group.
Invalidation: The live read weakens if participation falls to 4 of 13 members or fewer.
Who this business touches
The relationships behind ZYME
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ONCBeOne Medicines AGpartnerMay 7, 2026 ▾
“We have entered into separate collaboration and license agreements with BeOne Medicines Ltd.”
JAZZJazz Pharmaceuticals plcpartnerMay 7, 2026 ▾
“We have entered into separate collaboration and license agreements with BeOne Medicines Ltd.”
MRKMerck & Company, Inc.partnerMay 7, 2026 ▾
“Platform Partnerships We continue to have revenue-generating strategic partnerships and collaborations with respect to our Azymetric and EFECT therapeutic platforms with the following pharmaceutical companies: GlaxoSmithKline Intellectual Property Development…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 10 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ZYME is currently a Leader in the organic co-movement group Biotech Cancer Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.